Last reviewed · How we verify
Permethrin 1%
Permethrin 1% acts as an acaricide and insecticide by disrupting the nervous system of insects and arachnids.
Permethrin 1% acts as an acaricide and insecticide by disrupting the nervous system of insects and arachnids. Used for Treatment of head lice and scabies.
At a glance
| Generic name | Permethrin 1% |
|---|---|
| Also known as | NIX Creme Rinse |
| Sponsor | ParaPRO LLC |
| Drug class | pyrethroid |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Public Health |
| Phase | Phase 3 |
Mechanism of action
Permethrin 1% works by binding to the insect nervous system, causing hyperexcitation and eventual death. This mechanism is specific to the target species and does not affect mammals or other animals in the same way.
Approved indications
- Treatment of head lice and scabies
Common side effects
- Skin irritation
Key clinical trials
- Ivermectin Safety in Small Children (PHASE2)
- Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial (PHASE1, PHASE2)
- A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB (PHASE3)
- Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies (PHASE2)
- A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation (PHASE4)
- Efficacy of Three Novel Bi-treated Long Lasting Insecticidal Nets (NA)
- Adaptive Interventions for Optimizing Malaria Control: a Cluster-Randomized SMART Trial (NA)
- Sulfur vs. Different Regimes of Permethrin for Scabies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Permethrin 1% CI brief — competitive landscape report
- Permethrin 1% updates RSS · CI watch RSS
- ParaPRO LLC portfolio CI